NCT04659811 2026-04-15
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Phase 2 Active not recruiting
Clinical Trials
36 trialsNCT06649058 2026-04-15
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05222620 2026-04-13
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
Phase 2 Recruiting
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT04899908 2026-03-19
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT01644591 2026-03-05
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05419076 2026-02-11
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT02747303 2025-12-29
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
University of Chicago
Phase 2 Recruiting
NCT07304739 2025-12-26
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06020066 2025-09-15
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Fudan University
Phase 2 Active not recruiting
NCT04225039 2025-08-15
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
Phase 2 Active not recruiting
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03769103 2024-10-31
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT02107755 2024-05-21
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02886585 2024-03-12
Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT01622868 2023-10-17
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04671459 2023-06-28
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Phase 2 Unknown
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04650490 2023-03-02
STICk-IM-NSCLC
Duke University
Phase 2 Withdrawn
NCT05611645 2022-11-10
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Huashan Hospital
Phase 2 Unknown
NCT05177185 2022-02-16
HiSparCK
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00006386 2020-10-22
Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00006259 2020-07-27
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00587964 2016-02-22
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02662725 2016-01-25
IPI+RTS
University Hospital, Lille
Phase 2 Completed
NCT00811655 2013-11-25
Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Duke University
Phase 2 Terminated
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT01011231 2013-05-06
GKS
University of California, San Francisco
Phase 2 Terminated
NCT00003911 2013-01-31
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
SWOG Cancer Research Network
Phase 2 Terminated
NCT00253448 2011-08-29
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00484978 2007-06-12
Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT00004659 2005-06-24
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
Office of Rare Diseases (ORD)
Phase 2 Unknown